AIM vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AIM ImmunoTech exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a Current Ratio of 0.53, indicating a looming liquidity crisis. The company has suffered a catastrophic price collapse, falling from a 52-week high of $19.74 to $0.52, reflecting a near-total loss of investor confidence. While one analyst maintains a 'strong_buy' rating with a $10 target, this is completely decoupled from the fundamental reality of -53.3% revenue growth and an operating margin of -14,057%. The combination of negative growth, extreme valuation (P/S of 48.15), and failing health metrics suggests a high probability of insolvency or massive dilution.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AIM vs LLY: Head-to-Head Comparison
This page compares AIM ImmunoTech Inc. (AIM) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.